M

Metroplex Pulmonary and Sleep Center | McKinney, TX

Research site
(Unclaimed)
Location
4833 Medical Center Drive, Unit 6B, McKinney, Texas, United States of America

Site insights

Top conditions

Top treatments

INS018_055
BMS-986278
Dupilumab
AZLI
BLU-5937
SAR443765
Levomilnacipran
SAR440340
Tiotropium
Tiotropium Bromide

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 21 total trials

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-1)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling
Refractory Chronic Cough
Drug: BLU-5937
Drug: Placebo

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: BMS-986278 Placebo
Drug: BMS-986278

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Enrolling
Progressive Pulmonary Fibrosis
Drug: BMS-986278 Placebo
Drug: BMS-986278

This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab (SAR440340)
Locations recently updated

This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, saf...

Enrolling
Asthma
Drug: Placebo
Drug: Lunsekimig

Primary Objective:To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Inhaled Long-Acting Muscarinic Antagonist

This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to...

Enrolling
Asthma
Drug: Placebo
Drug: Dupilumab

The goal of this clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF).The primary objective is to evaluate...

Enrolling
Idiopathic Pulmonary Fibrosis (IPF)
Drug: Placebo
Drug: INS018_055

The goal of this clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF).The primary objective is to evaluate...

Active, not recruiting
Idiopathic Pulmonary Fibrosis (IPF)
Drug: INS018_055
Drug: Placebo

This is a pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR (Optimized Background Regimen) versus placebo + OBR in pati...

Active, not recruiting
MAC Lung Disease
Treatment Refractory MAC Lung Disease
Drug: Epetraborole
Drug: Placebo
Locations recently updated

Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a...

Enrolling
Progressive Pulmonary Fibrosis
Interstitial Lung Disease
Device: Treprostinil Ultrasonic Nebulizer
Drug: Placebo

The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment durat...

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: TTI-101
Drug: Placebo
Locations recently updated

Primary Objective:Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab SAR440340

Trial sponsors

Sanofi logo
Bristol-Myers Squibb (BMS) logo
I
V
A
Allergan logo
B
Gilead Sciences logo
Jazz Pharmaceuticals logo
Shionogi logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems